|1.||Matsuya, Yuji: 3 articles (12/2015 - 09/2009)|
|2.||Tohda, Chihiro: 3 articles (12/2015 - 09/2009)|
|3.||Sugimoto, Kenji: 2 articles (12/2015 - 02/2013)|
|4.||Teshigawara, Kiyoshi: 2 articles (02/2013 - 09/2009)|
|5.||Yajima, Hisanari: 1 article (12/2015)|
|6.||Terasaki, Sayuri: 1 article (12/2015)|
|7.||Hayashi, Yusuke: 1 article (12/2015)|
|8.||Minato, Daishiro: 1 article (12/2015)|
|9.||Shigyo, Michiko: 1 article (02/2013)|
|10.||Kuboyama, Tomoharu: 1 article (02/2013)|
|1.||Spinal Cord Injuries (Spinal Cord Injury)
02/01/2013 - "Denosomin improved hind limb motor dysfunction and axonal growth, especially in the 5-HT-positive tracts across the scar and increased the density of astrocytes. "
02/01/2013 - "Denosomin increased the ratio of astrocytes that secrete vimentin as an axonal growth facilitator, which, we propose enhances axonal growth beyond the glial scar and promotes functional recovery in SCI mice. "
02/01/2013 - "Denosomin increased the number of vimentin-expressing astrocytes inside glial scars of SCI mice, and 5-HT-positive axonal growth occurred in a vimentin-associated manner. "
|3.||Alzheimer Disease (Alzheimer's Disease)
12/04/2015 - "As an extension of previously conducted studies on developing an anti-Alzheimer's disease agent, denosomin (1-deoxy-24-norsominone, an artificial inducer of neurite elongation), derivatives were designed and synthesized based on the hypothesis that our denosomin would exhibit axonal extension activity via a 1,25D3-membrane-associated, rapid response steroid-binding protein (1,25D3-MARRS) pathway. "
12/04/2015 - "Synthesis of Denosomin-Vitamin D3 Hybrids and Evaluation of Their Anti-Alzheimer's Disease Activities."
09/03/2009 - "Synthesis of sominone and its derivatives based on an RCM strategy: discovery of a novel anti-Alzheimer's disease medicine candidate "denosomin"."
|2.||Carrier Proteins (Binding Protein)
|3.||Cholecalciferol (Vitamin D3)